Entries by

, , ,

FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1

Authors: Delia Soriano, Alicia Brusco, Laura Caltana Published in Behavioural Brain Research November 2020 Abstract Cannabinoid receptor type 1 (CB1R) is the most abundant cannabinoid receptor in central nervous system. Clinical studies and animal models have shown that the attenuation of endocannabinoid system signaling correlates with the development of psychiatric disorders such as anxiety, depression…

November 16, 2020 by
,

Cannabis Use May Reduce Healthcare Utilization and Improve Hospital Outcomes in Patients with Cirrhosis

Authors: Lindsay A. Sobotka, Khalid Mumtaz, Alice Hinton, Sean G. Kelly, Lanla F. Conteh, Anthony J. Michaels, A. James Hanje, Michael R. Wellnera Published in Annals of Hepatology November 2020 Abstract Introduction and Objectives:  Previous studies reveal conflicting data on the effect of cannabis use in patients with cirrhosis. This research evaluates the impact of…

November 12, 2020 by
,

Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD

Authors: Joshua L. Rein, Christina M. Wyatt Published in American Journal of Kidney Diseases August 2017 Abstract Marijuana is the most commonly used recreational drug in the United States, and legal recreational and medicinal use has gained public acceptance during the last decade. Twenty-nine US states have established medical marijuana programs, 8 of which have also…

November 11, 2020 by
,

Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy

Authors: Partha Mukhopadhyaya, Mohanraj Rajesha, Hao Pan, Vivek Patel, Bani Mukhopadhyaya, Sándor Bátkai, Bin Gao, György Haskóc, Pál Pachera Published in Journal of Pain and Symptom Management February 2010 Abstract Cisplatin is an important chemotherapeutic agent; however, its nephrotoxicity limits its clinical use. Enhanced inflammatory response and oxidative/nitrosative stress seem to play a key role in…

November 11, 2020 by
,

Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey

Authors: David Collister, MD, PhD, Karthik Tennankore, MD, SM, Sara N. Davison, MD, MHSc, Ron Wald, MD, MPH, Christian Rabbat, MD, MSc, Michael Walsh, MD, PhD Published in Journal of Pain and Symptom Management August 2020 Abstract Context: The efficacy and safety of cannabinoids to treat symptoms in individuals with kidney disease is uncertain. Objectives: We sought to…

November 11, 2020 by
,

Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome

Authors: Eszter Trojnar, Katalin Erdelyi,Csaba Matyas, Suxian Zhao, Janos Paloczi, Partha Mukhopadhyay, Zoltan V.Varga, Gyorgy Hasko, Pal Pacher Published in Free Radical Biology and Medicine May 2020 Abstract Study rationale: Hepatorenal syndrome (HRS) is a life-threatening complication of end-stage liver disease characterized by the rapid decline of kidney function. Herein, we explored the therapeutic potential of…

November 9, 2020 by
, , ,

Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study

Authors: Emily M.Webster, Ghanshyam S.Yadav, Stefan Gysler, Blair McNamara, Jonathan Black, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Christopher K. Arkfeld, Vaagn Andikyan, Gulden Menderes, Gloria Huang, Masoud Azodi, Dan-Arin Silasi, Alessandro D.Santin,Peter E.Schwartz, Elena S.Ratner, Gary Altwerger Published in Gynecologic Oncology Reports   November 2020 Abstract Research within a gynecologic oncology population has lagged behind…

November 9, 2020 by
,

Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft versus Host Disease

Authors: Cheng Yin Yuan, Vivian Zhou, Garrett Sauber, Todd M Stollenwerk, Richard Komorowski, Alicia López, Rosa Maria Tolon, Julian Romero, Cecilia J Hillard, William R Drobyski Published in Blood  October 2020 Abstract Graft versus host disease (GVHD) pathophysiology is a complex interplay between cells that comprise the adaptive and innate arms of the immune system….

November 9, 2020 by
,

Cannabidiol (CBD) as a Promising Anti-Cancer Drug

Authors: Emily S. Seltzer, Andrea K. Watters, Danny MacKenzie, Jr., Lauren M. Granat and Dong Zhang Published in Cancers  October 2020 Abstract Recently, cannabinoids, such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), have been the subject of intensive research and heavy scrutiny. Cannabinoids encompass a wide array of organic molecules, including those that are physiologically produced…

November 9, 2020 by
,

Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure

Authors: J. A. Garza-Cervantes, M. Ramos-González ,O. Lozano, C. Jerjes-Sánchez , and G. García-Rivas Published in Oxidative Medicine and Cellular Longevity October 2020 Abstract A large number of cannabinoids have been discovered that could play a role in mitigating cardiac affections. However, none of them has been as widely studied as cannabidiol (CBD), most likely…

November 5, 2020 by
,

The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities

Authors: Dixon H Xu, Benjamin D Cullen, Meng Tang, Yujiang Fang Published in Current Pharmaceutical Biotechnology  2020 Abstract Background: Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of…

November 5, 2020 by